Cost-Benefit Analysis of Hydrogen Breath Test-Directed Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome. | Walter W. Chan, MD, MPH, FACG, AGAF - Harvard University

Muratore A, Shah ED, Chan WW. Cost-Benefit Analysis of Hydrogen Breath Test-Directed Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023;21(10):2695-2696.e1.

Publisher's Version

Last updated on 08/31/2023
PubMed